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Abstract: Chlamydia trachomatis is the most common cause of bacterial sexually transmitted infections
and causes serious reproductive tract complications among women. The limitations of existing
oral antibiotics and treatment of antimicrobial resistance require alternative treatment options.
We are proposing, for the first time, the natural polyphenol resveratrol (RES) in an advanced delivery
system comprising liposomes incorporated in chitosan hydrogel, for the localized treatment of
C. trachomatis infection. Both free RES and RES liposomes-in-hydrogel inhibited the propagation
of C. trachomatis in a concentration-dependent manner, assessed by the commonly used in vitro
model comprising McCoy cells. However, for lower concentrations, the anti-chlamydial effect of RES
was enhanced when incorporated into a liposomes-in-hydrogel delivery system, with inhibition of
78% and 94% for 1.5 and 3 µg/mL RES, respectively for RES liposomes-in-hydrogel, compared to
43% and 72%, respectively, for free RES. Furthermore, RES liposomes-in-hydrogel exhibited strong
anti-inflammatory activity in vitro, in a concentration-dependent inhibition of nitric oxide production
in the LPS-induced macrophages (RAW 264.7). The combination of a natural substance exhibiting
multi-targeted pharmacological properties, and a delivery system that provides enhanced activity
as well as applicability for vaginal administration, could be a promising option for the localized
treatment of C. trachomatis infection.
Keywords: resveratrol; chitosan; liposomes; hydrogel; Chlamydia trachomatis; antimicrobial; vaginal therapy
1. Introduction
Chlamydia trachomatis is a major cause of sexually transmitted infections (STIs) with more than
127 million new infections reported globally each year [1]. It is responsible for serious reproductive tract
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complications among women, affecting their health and wellbeing. Due to its asymptomatic nature,
the reported number of infections is probably underestimated. C. trachomatis is a small obligate
intracellular bacterial pathogen with a specialized biphasic life cycle. The bacterium exists in two forms;
the infectious elementary body and non-infectious reticulate body that conceals its antigenic profile
from the immune system by replicating in an intracellular vacuole and then moving between the hosts in
the non-replicative form [2]. Current treatment of C. trachomatis infections includes orally administered
azithromycin (AZT) or doxycycline, however, they may have subsequent side effects; moreover,
clinical failure and high recurrence rates do represent an increasing concern. In addition, tetracyclines
are contraindicated during pregnancy [3]. Although the proofs that antimicrobial resistance (AMR) is
a cause of the current therapy failure remains to be widely discussed, there is clear evidence of in vitro
heterotypic resistance to conventional antibiotics at high levels of organism load [4]. The extensive use
of a single dose of AZT for uncomplicated chlamydia infections is questionable [3], whereas the efficacy
of conventional treatment is threatened by the continuous rise of AMR and might become limited [4–6].
Treatment failure or even the lack of treatment can be associated with serious consequences such
as ectopic pregnancy and tubal infertility [7]. In the search for novel tools to tackle AMR, natural
substances with multi-targeted pharmacological properties have emerged as possible alternatives to
antibiotics [8], including for the treatment of C. trachomatis infections [9,10].
Resveratrol (RES) is a substance of natural origin that is gaining much attention due to its many
potential health benefits. Moreover, it is found to be safe and well tolerated [11]; hence, RES is a promising
compound for pharmaceutical applications, including those for vaginal administration. In addition to
its known anti-oxidative and anti-inflammatory properties, in recent years, its antimicrobial activities
highlighted RES as an interesting alternative to antibiotics [11,12]. A wide range of bacterial, viral and
fungal species are known to be susceptible to RES, including C. trachomatis [13,14]. The anti-chlamydial
effect of RES is not yet completely understood, however, inactivation of the efflux pump [15],
inhibition of bacterial type III secretion system (T3SS) [16–18] and prevention of cell entry by covalently
binding to the elementary body of C. trachomatis [17] are all suggested as possible mechanisms for
bacterial growth inhibition. Since RES is a poorly water soluble substance and has rather limited
bioavailability and stability, a suitable delivery system is required to obtain optimal therapeutic
effect [19]. When aiming for localized treatment of vaginal infections, the delivery system must hold
the necessary characteristics needed to assure a uniform distribution throughout the vaginal cavity
and a sufficient drug concentration at vaginal site for an adequate amount of time. Simultaneously,
the system should improve the solubility of RES and protect the active ingredient to assure its stability
and activity at vaginal site. We therefore proposed RES liposomes-in-hydrogel as a superior formulation
targeting vaginal chlamydia infection.
The proposed delivery system comprises RES liposomes incorporated into chitosan hydrogels,
where chitosan hydrogel enables an appropriate distribution and assures a prolonged contact time at
the vaginal site, whereas liposomes tackle the solubility and stability issues of RES. The combination
of the two delivery systems should enhance the antimicrobial effect of RES and enable a successful
localized treatment. We therefore, as the first stage, challenged the novel RES liposomes-in-hydrogel
formulation against C. trachomatis using the commonly applied cell line for chlamydial infections,
namely McCoy cells [14,20], under in vitro conditions. Further, its anti-inflammatory activity was
evaluated to support the superiority of the novel formulation.
2. Materials and Methods
2.1. Materials
Lipoid S 100 (>94% phosphatidylcholine) was provided by Lipoid GmbH, Ludwigshafen, Germany.
Chitosan (medium molecular weight hydramer HCMF (350–600 kDa), degree of deacetylation 70–95%)
was provided by Chitinor, Tromsø, Norway. McCoy mouse fibroblast (ECACC 90010305), Resveratrol
(RES: 3,5,4′-trihydroxy-trans-stilbene, purity ≥99%), acetic acid, glycerol, Dulbecco’s modified
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eagle medium (DMEM)—high glucose, Hank’s balanced salt solution, cyclohexemide, glutamine,
sodium phosphate, sucrose, potassium dihydrogen phosphate, glutamic acid, propylene glycol,
RPMI 1640 medium and bovine serum albumin were the products of Sigma-Aldrich, Chemie GmbH,
Steinheim, Germany. Chlamydia trachomatis Serovar E (ATCC® VR-348B™) was purchased from
LGC Standards GmbH, Wesel, Germany. Pathfinder™ Chlamydia Culture Confirmation System was
the product of Bio-Rad Laboratories AB, Oslo, Norway. Azithromycin (AZT) was a gift from PLIVA
Croatia Ltd., Zagreb, Croatia. Fetal Bovine Serum (FBS) and lipopolysaccharide (LPS; Escherichia coli,
055:B5) was purchased from Sigma Life Science (Sigma—Aldrich Norway AS, Oslo, Norway).
Griess reagent: phosphoric acid, sulfanilamide and naphthylethylenediamine dihydrochloride were all
products of Sigma-Aldrich Norway AS, Oslo. Murine macrophages RAW264.7 cells were from ATCC,
Manassas, VA, USA. Uranyless was the product of Electron Microscopy Sciences, Hatfield, PA, USA.
All chemicals were of analytical grade.
2.2. Preparation of RES Liposomes
Liposomes were prepared by the film hydration method [19]. Briefly, RES (10 mg) was dissolved
in ethanol and Lipoid S 100 (200 mg) was dissolved in methanol. The solutions were mixed and
solvents were removed by evaporation (Büchi rotavapor R-124 with vacuum controller B-721, Büchi
Vac® V-500, Büchi Labortechnik, Flawil, Switzerland) for 3 h at 50 mm Hg and 50 ◦C. Distilled water
(10 mL) was added to the dry lipid film and shaken to generate liposomes. Liposomal suspension was
stored in a refrigerator (4–8 ◦C) overnight prior to further use. Plain liposomes (not containing RES)
were prepared in similar manner.
Extrusion through polycarbonate membranes (Nuclepore Track-Etch Membran, Whatman House,
Maidstone, UK) was applied for vesicle size reduction [21]. This was done stepwise through 0.4,
0.2 and 0.1 µm pore size filters, each step repeated 5 times. Extruded liposomes were stored in a
refrigerator overnight, prior to characterization and further use.
2.3. Characterization of RES Liposomes
Liposomal size distribution was determined by photon correlation spectroscopy (Submicron
particle sizer model 370, Nicomp, Santa Barbara, CA, USA). All sample preparations were done in
a laminar airflow bench and liposomal size analyses were run in vesicle mode and intensity-weight
distribution. Three parallels, with a run time of 10 min, were done for all samples.
Malvern Zetasizer Nano Z (Malvern, Oxford, UK) was used in the determination of zeta potential as
previously described [22]. Samples were diluted in filtrated water (0.2µm) to appropriate concentrations
as previously described. Prior to measurements, the Zetasizer measurement cells (DTS1060) were
rinsed with ethanol and filtrated water, respectively. Three parallels were measured at 25 ◦C for
all samples.
Dialysis was applied to separate free RES from liposomally entrapped RES (Mw cutoff:
12–14,000 Da, Medicell International Ltd., London, UK). Distilled water was used as the dialysis
medium in a ratio of 1:250 mL to assure the solubility of RES [19]. After 4 h of dialysis, aliquots of
both sample and dialysis medium were diluted in methanol and measured spectrophotometrically
(Microtitre plate reader; Spectra Max 190 Microplate, spectrophotometer, Molecular Devices, Sunnyvale,
CA, USA) at 306 nm to determine RES entrapment efficiency.
The morphology of RES liposomes was inspected by transmission electron microscopy (TEM).
Liposomal formulations were deposited on glow discharged 200 or 400 mesh carbon-coated grids for
5 min. The samples were stained with uranyless for 10–40 s and air-dried for 30 min prior to imaging,
using the HT7800 (Hitachi, Tokyo, Japan) at 20–120 kV acceleration voltage equipped with a Morada
digital camera.
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2.4. Preparation of RES Liposomes-In-Hydrogel Formulation
Chitosan hydrogels were prepared as previously described [8]. In brief, medium molecular
weight chitosan (350–600 kDa, DD 70–95%) was dispersed in a mixture of 1% (w/w) acetic acid and
10% (w/w) glycerol, to a final polymer concentration of 2.5% (w/w). The hydrogels were left to swell
at room temperature (23–25 ◦C) for 48 h. Liposomes containing RES (free of unentrapped RES)
were evenly distributed in the chitosan hydrogel by careful hand stirring. Formulations with a final
concentration of 20% (w/w) liposomal suspension were prepared, corresponding to 166–174 µg/g RES
in formulation.
2.5. In Vitro RES Release
RES release was determined by a spiral release system (developed at the University of Freiburg,
Freiburg, Germany) which is suitable for the release studies of semi-solid formulations such as
hydrogels [23]. Formulations and controls (20 g, containing 3.3–3.5 mg of RES) were weighed in
the donor part of the system and connected to the receptor part, separated by the cellophane membrane.
Receptor medium (400 mL acetate buffer, pH 4.6) was kept at a temperature of 37 ◦C and continuously
flushed through the receptor part of the system (at 100 rpm). Samples (500 µL) were taken after
1, 2, 3, 4, 6 and 8 h and replaced with fresh buffer. RES content in all samples was measured
spectrophotometrically at 306 nm.
2.6. McCoy Cell Culture and Propagation of Chlamydia trachomatis
McCoy cells were grown in high glucose Dulbecco’s modified Eagles’ medium (DMEM)
supplemented with 10% heat inactivated fetal bovine serum (FBS) and 2 mM glutamine in Corning®
T75 flasks (Sigma-Aldrich). To avoid the synergistic effect of antibiotics and RES, the cells were
grown in the absence of antibiotics for 5 passages before aliquoted in 24-well plates. Cell monolayers
were infected with C. trachomatis diluted in SPG (250 mM sucrose, 10 mM sodium phosphate, 5 mM
potassium dihydrogen phosphate, 5 mM glutamic acid). Plates were centrifuged for 1 h at 2000× g
and incubated for 1 h at 37 ◦C and 5% CO2. Media was replaced with fresh media supplemented
with additional 5% glucose and 0.5 µg/mL cycloheximide and incubated for 48 h at 37 ◦C and 5% CO2.
For the cells receiving treatment: RES liposomes, RES liposomes-in-hydrogel, respective controls and
positive control (AZT) were prepared in the fresh media in the RES concentrations of 1.5, 3 and 6 µg/mL,
respectively. The treatment was added 2 h post-infection and the cells were incubated further at 37 ◦C
and 5% CO2. The media was removed and methanol was added to fix the cells at 48 h post-infection.
The Pathfinder™ Chlamydia Culture Confirmation System (Bio-Rad Laboratories AB, Oslo, Norway)
was used in staining of the inclusions [24]. The plates were inspected under fluorescence microscope
(Leica DMI6000B microscope with Leica DFC320 digital camera, Leica Microsystems, Wetzlar, Germany)
and 5 pictures (10×) were taken in similar areas of each well to determine the number of inclusions.
Susceptibility testing was performed in duplicate and the experiment was performed in quadruple.
2.7. Inhibition of NO Production
Anti-inflammatory activity of RES formulation was expressed by measuring its inhibition activity
on the nitric oxide (NO) production in LPS-induced macrophage (RAW 264.7 cells), as described
earlier [25]. Macrophages (1× 105 cells/well) were incubated in a 24-wells plate with RPMI 1640 medium
with additional 10% fetal bovine serum (FBS) and glutamine at 37 ◦C and 5% CO2. After 24 h, the medium
was replaced with fresh media containing 1 µg/mL of LPS to induce inflammation. Media (10 µL) was
used as the negative control and media with LPS (10 µL) as the positive control. The test samples of
various formulations were homogenized in media to obtain the RES concentrations of 50, 500 and
2500 ng/mL that were added to the wells containing cells with LPS media. Cells were incubated
for 24 h at 37 ◦C and 5% CO2 to observe anti-inflammatory effects of the samples. Media (0.3 mL)
was collected from each well, mixed with an equal volume of Griess reagent (1% sulfanilamide,
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0.1% naphthylethylenediamine dihydrochloride, 2.5% phosphoric acid) and incubated for 30 min [8].
The macrophage challenged with LPS produced NO which was stabilized as nitrite in the media,
corresponding to NO produced by the cells. The nitrite in media after the reaction with the Griess
reagent was measured spectrophotometrically (Agilent Technologies, Santa Clara, CA, USA) at 540 nm.
The relative anti-inflammatory effects of the formulations on the inhibition of NO production was
expressed in a percentage, compared to corresponding controls (cells treated with 1 µg/mL LPS).
2.8. Statistical Analyses
We used the student’s t-test to compare the means. A p-value less than 0.05 was considered
statistically significant.
3. Results
3.1. Characteristics of Liposomes-in-Hydrogel Formulation
The liposomes, both plain and RES liposomes, were characterized by measuring the vesicle size,
size distribution, zeta potential and RES entrapment efficiency (Table 1). The liposomes were found to
be in the desired size range between 100 and 200 nm [8], with average vesicle size of 156 ± 21 nm and
158 ± 22 nm for plain and RES liposomes, respectively. The low polydispersity index (PDI, 0.073 and
0.077 for plain and RES liposomes, respectively), indicated that the majority of liposomes were of
similar size. The obtained entrapment efficiency of 85% (from starting amount of RES) was quite high
and also corresponded to our own and literature data [8,19,26–28]. Both plain and RES liposomes
exhibited a close to neutral zeta potential (−0.56 ± 0.86 mV and −6.72 ± 2.47 mV for plain and RES
liposomes, respectively), as expected [8,19]. TEM images (Supplementary Figure S1) of RES liposomes
displayed a spherical morphology and size corresponding to the size reported in Table 1.
Table 1. Characteristics of plain and RES liposomes. Results are expressed as mean ± SD (n = 3).
Formulation Vesicle Size(nm) PDI *
Zeta Potential
(mV) Entrapment Efficiency (%)
Plain liposomes 156 ± 21 0.073 −0.56 ± 0.86 -
RES liposomes 158 ± 22 0.077 −6.72 ± 2.47 85 ± 2
* Polydispersity index.
Based on optimal texture properties of liposomes-in-hydrogel for vaginal application [8],
RES liposomes (20%, w/w) were incorporated into chitosan hydrogel with a final polymer concentration
of 2.5% (w/w). To assure that RES was indeed available to exhibit antimicrobial action, both formulated
as RES liposomes or as RES liposomes-in-hydrogel, the in vitro RES release from RES liposomes and RES
liposomes-in-hydrogel formulation was compared to the amount of RES from solution (control; RES in
propylene glycol) permeating the membrane. To deal with the very limited solubility of RES in water,
for RES in solution we used propylene glycol as a solvent to produce the control solution. We were
aware that propylene glycol may induce the osmotic effects resulting in enhanced permeation, however,
the option of solvents was limited. The amount of RES permeating the membrane, reflecting the
RES released from formulations, was measured for up to 8 h considering the overnight application;
for the control (free RES), more than 90% (>3050 µg) of RES permeated the membrane as compared
to 38% (1300 µg) RES released from RES liposomes-in-hydrogel. Furthermore, the RES release from
RES liposomes and RES in hydrogel was measured. After 8 h, more than 70% (>2400 µg) of RES was
released from the RES hydrogel, while 61% (2050 µg) of liposomal RES was released. These results
correspond to earlier findings assessed in another experimental setup, namely the Franz diffusion cell
system [8]. Both liposomal and hydrogel formulations exhibited a sustained RES release that was
further enhanced by the combination of the two delivery systems (p < 0.005), providing a prolonged
release and probable prolonged effect (Figure 1).
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3.2. C. trachomatis RES Challenge In Vitro
C. trachomatis has been reported to be susceptible to RES [13,14]. However, the solubility and
stability of polyphenol RES are limited and a delivery system is needed when considering the potential
use of RES as a localized antimicrobial treatment. The ability of RES in different formulations to interfere
with C. trachomatis viability was therefore tested. The commonly prescribed oral antibiotic AZT was
used as a positive control; as expected AZT completely reduced the bacterial growth. A clear reduction
in the number of C. trachomatis-infected cells was observed after treatment with RES (Figures 2 and 3).
RES liposomes-in-hydrogel expressed superior anti-chlamydial activity in the lower concentrations
with inhibition of 78%, 94% and 95%, for 1.5, 3 and 6 µg/mL RES, respectively, compared to 43%, 72%
and 99%, respectively, for the free RES (control). Moreover, RES liposomes exhibited a dose-dependent
anti-chlamydia effect with inhibition of 57%, 75% and 94%, for 1.5, 3 and 6 µg/mL RES, respectively.
However, the RES in hydrogel showed a reduced effect compared to free RES (Figure 3). As expected,
plain liposomes, plain chitosan hydrogel and plain liposomes-in-hydrogel did not show any significant
inhibition of C. trachomatis (2%, 7% and 6% inhibition at 6 µg/mL, respectively), indicating that
the delivery systems alone do not exhibit anti-chlamydia effect (data not included in figures). However,
when comparing the antibacterial effect of free RES (control) and RES liposomes-in-hydrogel, the activity
of RES at lower concentrations is clearly enhanced (p < 0.05, for both 1.5 and 3 µg/mL) when RES is
formulated in the liposomes-in-hydrogel delivery system. None of the tested formulations showed any
visible effect on cell count and viability, in agreement with earlier studies that indicated that the RES
liposomes-in-hydrogel formulation is non-toxic at lipid concentrations up to 50 µg/mL [8].
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3.3. Anti-I flammatory Effect of RES Liposomes-In-Hydrogel
We have previously reported on the anti-inflammatory properties of RES and RES liposomes
where the NO production in LPS-challenged macrophage was strongly inhibited, and RES liposomes
formulation was found to be more potent than free RES [19]. However, the anti-inflammatory effects of
RES liposomes-in-hydrogels has not yet been reported. We therefore studied the effect of free RES (control),
RES liposomes-in-hy rogel, RES in hydrogel and RES liposomes on the inhibition of NO production.
The NO roductio in the LPS challenged cells was inhibited in a conc ntration-dep ndent manner by
all formulations. The effect of RES when formulated in hy rogel was clearly en anced compared to
the control, hence, the effect of plain hydrogel and plai liposomes-in-hydrogel was included in testi g.
The result showed a pron unced inhibition of NO productio of the delivery s stem even without
the active ingredi nt, however, the hydrogel alone expressed limited or no reduction at the lower
concentrations. The NO production inhibition of RES lipos mes-in-hydrogel was superior to both RES
in hydrogel and plain liposomes-in-hydrogel for the higher concentrations tested (T ble 2, p < 0.05).
Table 2. Effect of RES formulations on the NO production expressed as the percenta e of reduction
(n = 3). Concentration of formulations is expressed as RES concentrations (50, 500 and 2500 ng/mL).
RES Formulation 50 ng/mL 500 ng/mL 2500 ng/mL
Control * 3 ± 3 11 ± 2 24 ± 1
RES liposomes-in-hydrogel 15 ± 2 37 ± 5 a 58 ± 4 b
Control * in hydrogel 10 ± 3 18 ± 3 a 51 ± 1 b
RES liposomes 9 ± 2 12 ± 2 16 ± 6
Plain liposomes-in-hydrogel ** 17 ± 5 21 ± 1 46 ± 3
Plain hydrogel ** 0 ± 1 7 ± 4 54 ± 3
* RES in propylene glycol, ** adjusted to concentration in formulations, a p < 0.005, b p < 0.05.
4. Discussion
In the era of AMR, the search for novel antimicrobials has intensified. Natural origin substances
with known antimicrobial activities offer the possibility to act as alternatives to antibiotics or a means
to increase the efficacy of conventional antibiotics [29]. Due to its anti-oxidative, anti-inflammatory
and antimicrobial properties, the natural polyphenol RES could be the ideal active molecule.
The antimicrobial effects of RES have been recently reported [11,30] and over the last few years,
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the number of publications on RES in various delivery systems increased significantly [31–35]. Due to
its poor solubility and limited stability, there is a need for a delivery system that can protect RES
from environmental and chemical changes, as well as enable its depot at the site of action to fully
utilize its therapeutic properties [36]. In addition, by efficiently treating the infections locally while
avoiding the systemic exposure to antimicrobials, we could reduce the side effects and improve
its safety, as well as limit the chance for development of AMR. However, the vaginal site comprises
intrinsic challenges [8] that need to be overcome by development of smart formulations which enhance
the efficacy while improving the stability of RES. The localized treatment of vaginal infections requires a
delivery system with suitable properties to assure a uniform distribution over vaginal tissue, a sufficient
contact time and an adequate drug concentration at targeted site [37]. Chitosan hydrogels have a
low pH (4–5), are biodegradable and exhibit excellent mucoadhesive properties; these are qualities
that are considered desirable for vaginal drug delivery [38]. Various nanocarriers have the ability
to increase the potency of active substances and constitute an important part in the treatment of
infectious diseases [39]. Liposomes are known to improve RES solubility and to provide its sustained
delivery [8,19,26,32]. Furthermore, liposomes are shown to improve its chemical stability, enabling
therapeutic benefits [40–42]. Incorporation into liposomes allows RES to better merge with bacterial cells,
resulting in an improved antimicrobial effect, even at lower doses [40]. Liposomes were also able
to protect incorporated antibiotics, such as vancomycin, from degradation and increase its potency
against bacteria [43]. Recently, the local therapy by liposomes containing AZT, which is commonly
used as an oral single-dose in chlamydia treatment, has shown efficacy against cervicovaginal bacterial
infections [44]. Moreover, incorporation of liposomes into hydrogels has shown an ability to assure
hydrogel stability [8], and hydrogels in liposomes-in-hydrogels act on improving the stability of
incorporated liposomes by preserving their original vesicle size [45].
4.1. RES Liposomes-In-Hydrogel Formulation
To assure successful localized treatment of vaginal infections such as chlamydia, the delivery
system should provide an adequate drug concentration at the site of infection for a sufficient amount
of time. Several studies support the hypothesis that the liposomal formulation of RES improves its
therapeutic benefits by improving its solubility and chemical stability [41,42,46]. Moreover, the storage
stability of liposomes can be improved by polyphenol incorporation, due to their inherent anti-oxidative
properties [41]. An appropriate liposomal vesicle size for local administration is necessary to enable a
depot effect and avoid a systemic effect. The reduction of vesicle size can lead to a loss of originally
entrapped material, in our case the RES load, however, the smaller vesicle size did not compromise
the RES entrapment efficiency that was found to be sufficiently high, with an average of 85% RES
in liposomes (Table 1). Additionally, the very low polydispersity index (PDI) denotes a narrow
liposomal size distribution. The incorporation of liposomes into chitosan hydrogel has shown
improvement of the gel’s texture properties [8] as well as providing an appropriate viscosity for vaginal
application [47]. The cohesiveness and adhesiveness of hydrogels were reduced in the presence of
vaginal fluids, however, liposomes were shown to stabilize the chitosan network [48]. Considering the
incorporation of neutral liposomes into chitosan hydrogel, that comprises positively charged chains,
potential disturbance of the liposomal membrane and rapid release of the entrapped substance
is avoided [49]. Accordingly, a consistent and sustained RES release from liposomes-in-hydrogel
formulation was confirmed (Figure 1), in agreement with earlier findings utilizing the Franz diffusion
cell system [8]. Although both liposomal and hydrogel formulations exhibited a sustained RES release,
the release was further sustained by the combination of the two delivery systems. This indicates
a synergy effect on the release, and contributed to the fact that the RES has to be released from
the liposomes first, followed by release from hydrogel in the case of the RES liposomes-in-hydrogel
formulation. Considering the potential biological activities of RES, the concentration of released
RES from the liposomes-in-hydrogel system is above the effective concentration required to induce
the desired effect in the C. trachomatis challenge in vitro. The in vitro release study presented in
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Figure 1 revealed that the amount of RES released from the liposomes-in-hydrogel formulation (after
8 h) was more than 1300 µg (~38% of the starting amount). For the formulation volume applied in
anti-chlamydial challenge (starting RES concentration of 6 µg/mL), the RES amount released after 8 h
would correspond to 2.3 µg (2.3 µg/mL). Our results in Figure 3 indicate a potent anti-chlamydial
activity at RES concentration as low as 1.5 µg/mL. We therefore expect that the amount of RES released
from the formulation is above the required effective concentration. The use of hydrogels as vaginal
formulations, due to the sustained release of active substances has a consequent therapeutic effect which
is favorable [50]. Additionally, we have earlier confirmed in an ex vivo RES penetration study through
sheep vaginal tissue a very limited RES penetration from liposomes (4.5–5%), while the majority of RES
was found within or retained on the tissue [8], confirming the lack of its systemic effect. This would
enable safe administration of RES formulations to pregnant patients as well.
4.2. Anti-Chlamydial Activity
The ability of RES to inhibit propagation of C. trachomatis in McCoy cells was recently reported [14].
RES assured a dose-dependent reduction in the number of infected cells. The liposomes-in-hydrogel
system is expected to enhance the RES activity, especially considering that RES has to be protected
from environmental and chemical changes to exert full therapeutic potential [34]. Accordingly,
RES liposomes-in-hydrogel exhibited potent anti-chlamydial activity (Figures 2 and 3) and was found
superior to free RES (control) in lower concentrations (p < 0.05). Additionally, liposomal RES expressed
a high inhibition of C. trachomatis, confirming that the effect of RES is not reduced by liposomal
entrapment. Literature supports the finding that liposomal entrapment of RES improves its ability to
merge with bacterial cells, leading to an enhanced antimicrobial effect [40]. However, RES in hydrogel
did not succeed to inhibit the propagation of C. trachomatis (Figure 3). This is a strong indication that
the ability of liposomes to assure RES stability and protect the incorporated RES is of importance
for its therapeutic effect. Considering the conditions at vaginal site, the mucoadhesive properties
assured by chitosan hydrogel are necessary [48], and studies show that the use of hydrogels is essential
when aiming for improved therapy by the vaginal route [51]. Recent findings confirmed that chitosan
hydrogel has intrinsic antibacterial activity [48], however, C. trachomatis was not inhibited by chitosan
hydrogel on its own. It is therefore evident that for full utilization of RES as a potential anti-chlamydial
treatment, both liposomes as a primary delivery system and chitosan hydrogel as a secondary vehicle
are required.
We are highly encouraged by the in vitro findings, however, the results need to be explored in vivo
to determine clinical relevance. In parallel, the exact mechanism of bacterial growth inhibition by
RES should be fully mapped to assist in the optimization of the vehicle to be used to deliver RES into
the infected cells [11,14]. The mechanism of antibacterial action of RES is not completely understood,
however, the inhibition of the ATP synthase, DNA fragmentation and membrane damage might be
involved [11,12,52]. Regarding the inhibition of C. trachomatis, the inclusion membrane presents an
additional barrier that has to be crossed to reach the intracellular bacteria. RES is generally found to be
less active against gram-negative bacteria compared to gram-positive, possibly due to the efflux pump
systems in gram-negative species [11,53]. Hence, the inactivation of the efflux pump can increase
the antibacterial activity of RES [15]. Moreover, C. trachomatis possesses a bacterial type III secretion
system (T3SS), which might facilitate the entry of bacteria into the host cell, thus presenting a target
for bacterial growth inhibition [16–18]. Several monomers, dimers and oligomers of RES have shown
to inhibit the T3SS in various bacteria [54], including C. trachomatis. Although the C. trachomatis
inclusion membrane presents an additional barrier, it also has low permeability for larger compounds,
and Zetterström and colleagues hypothesized that the RES tetramer (-)-hopeaphenol covalently
binds to the elementary body of C. trachomatis and thereby prevents cell entry and intracellular
replication [17]. In the present work, the treatment was added post-infection, which implies that RES
affects the intracellular stage of the C. trachomatis life-cycle. This indicates that the incorporation into
liposomes allows RES to interfere with bacterial cells, achieving an improved antimicrobial effect
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at lower doses. It is assumed that liposome membranes fuse with the cell membranes, improving
the delivery of RES to the cells [40]. It is worth noting that lipids in liposomes, chitosan and RES are
all of natural origin and they are confirmed to be non-toxic [8]. Liposomes are also considered to be
favorable nanocarriers when aiming for localized treatment, as they do not interfere with the vaginal
microbiota [55].
RES liposomes-in-hydrogel offers an additional advantage which is currently one of our interests.
Namely, vaginal infections are often associated with the formation of biofilms which can decrease
the susceptibility to antimicrobial agents and increase the hazard of AMR. Nanoparticles have shown
an ability to penetrate biofilms and have great potential in the treatment of challenging infections [56].
Moreover, since chitosan hydrogel efficiently disrupts vaginal biofilms [57], while RES inhibits
the bacterial biofilm formation [58], the proposed RES liposomes-in-hydrogel might be targeted and
utilized for the treatment of other types of vaginal infections.
4.3. Anti-Inflammatory Activity
Vaginal inflammation is very common and often associated with vaginal infection, including
by bacteria such as C. trachomatis. Cervical cells infected with C. trachomatis activates the release of
pro-inflammatory cytokines [59]. Some free radicals, such as nitric oxide (NO•), are responsible for
mediating the inflammation; we therefore tested the ability of RES formulations to inhibit NO production.
We reported earlier that liposomal RES exhibited a stronger inhibition of both NO and TNF-αproduction
in LPS-induced macrophages compared to the free RES [15]. The findings in the current study show that
the effect of RES upon incorporation into formulation (liposomes-in-hydrogel) was clearly enhanced
(p < 0.05) compared to free RES (Table 2). Interestingly, the effect of RES when in hydrogel was also
noticeably enhanced. Consequently, we evaluated the ability of plain liposomes-in-hydrogel to inhibit
NO production; a relatively high anti-inflammatory effect was measured for the delivery system
without RES. However, the hydrogel on its own expressed anti-inflammatory activity only at the highest
concentration. The superior inhibition determined for RES liposomes-in-hydrogel, as compared to both
RES in hydrogel and plain liposomes-in-hydrogel, suggests a synergy of the liposomes-in-hydrogel
formulation and the incorporated active ingredient. The ability of the novel formulation to provide an
anti-inflammatory effect would be highly beneficial, considering the success of treatment.
5. Conclusions
Liposomes-in-hydrogel formulation containing the natural substance RES as the active ingredient
with high RES load was prepared, assuring sustained RES release. The incorporation of RES into
the liposomes-in-hydrogel delivery system clearly enhanced the anti-chlamydial effect of RES at lower
concentrations, indicating the need for a delivery system to assure successful therapy. Moreover,
the delivery system enhanced the anti-inflammatory activity of RES. Finally, the use of alternative
antimicrobials, such as RES, can preserve available antibiotics as efficient drugs in the future.
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